AnnouncementJanuary 15, 2025
Baseline Therapeutics Announces Phase 3 Trial for Alcohol Use Disorder
BT-001 enters pivotal phase with FDA pre-IND validation, positioning for market leadership in AUD treatment.
News
ResearchJanuary 10, 2025
New Data Shows Promise for GLP-1RAs in Stimulant Use Disorders
Preclinical studies demonstrate potential efficacy in cocaine and methamphetamine use disorder populations.
PartnershipJanuary 5, 2025
Baseline Partners with Leading Academic Medical Centers
Strategic collaborations expand clinical trial network and accelerate patient recruitment.
PolicyDecember 20, 2024
Addressing the Treatment Gap in Substance Use Disorders
Only 3% of AUD patients currently receive treatment. Baseline is working to change that.
ScienceDecember 15, 2024
Understanding GLP-1RA Mechanisms in Addiction Treatment
Deep dive into the biological pathways that make GLP-1 receptor agonists effective for substance use disorders.
CompanyDecember 10, 2024
Baseline Therapeutics Secures Series A Funding
Investment enables acceleration of clinical development programs across multiple indications.